Nevro Corp. (NVRO)
| Market Cap | 1.67B |
| Revenue (ttm) | 386.14M |
| Net Income (ttm) | -136.12M |
| Shares Out | 35.26M |
| EPS (ttm) | -3.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 693,195 |
| Open | 47.40 |
| Previous Close | 46.14 |
| Day's Range | 45.94 - 48.33 |
| 52-Week Range | 41.74 - 182.45 |
| Beta | 1.03 |
| Analysts | Hold |
| Price Target | 80.48 (+69.8%) |
| Earnings Date | May 4, 2022 |
About NVRO
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and ...
Financial Performance
In 2021, Nevro's revenue was $386.91 million, an increase of 6.87% compared to the previous year's $362.05 million. Losses were -$131.36 million, 58.1% more than in 2020.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for NVRO stock is "Hold." The 12-month stock price forecast is 80.48, which is an increase of 69.79% from the latest price.
News
Nevro (NVRO) Stock Falls 19% Despite Q1 Earnings Beat
Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q1 partly due to soft domestic performance.
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
Nevro (NVRO) delivered earnings and revenue surprises of 11.71% and 2.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Nevro Reports First Quarter 2022 Financial Results, Provides Second Quarter 2022 Guidance and Reiterates Full-Year 20...
REDWOOD CITY, Calif. , May 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for...
Analysts Estimate Nevro (NVRO) to Report a Decline in Earnings: What to Look Out for
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nevro to Report First Quarter 2022 Financial Results
Company to Host Conference Call on Wednesday, May 4, 2022 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , April 6, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that i...
Here's Why You Should Retain Nevro (NVRO) Stock For Now
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Nevro's (NVRO) PDN Therapy Gets Noridian's Medicare Coverage
Latest favorable coverage decision for Nevro's (NVRO) PDN Therapy by Noridian is expected to allow the former to serve a wider patient pool.
Nevro Announces Positive Medicare Coverage Update from Noridian for the Treatment of Painful Diabetic Neuropathy
REDWOOD CITY, Calif., March 7, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...
Nevro's (NVRO) Q4 Earnings in Line, Revenues Beat Estimates
Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q4 due to soft geographical performances.
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
Nevro (NVRO) delivered earnings and revenue surprises of 0% and 0.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Nevro Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides First Quarter and Full-Year 2022 Guidance
REDWOOD CITY, Calif., Feb. 23, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results fo...
Nevro to Participate in Wells Fargo 2022 MedTech R&D Spotlight Call Series
REDWOOD CITY, Calif., Feb. 18, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...
Nevro Announces Publication of 12-Month Data from SENZA-NSRBP Randomized Controlled Trial in Journal of Neurosurgery:...
REDWOOD CITY, Calif., Feb. 11, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...
Nevro to Present at Citi's 2022 Virtual Healthcare Conference
REDWOOD CITY, Calif., Jan. 31, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...
Nevro Named to 2022 Bloomberg Gender-Equality Index
REDWOOD CITY, Calif., Jan. 26, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...
Nevro Responds to Competitor's Announcement of FDA Approval for Painful Diabetic Neuropathy
REDWOOD CITY, Calif., Jan. 25, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...
Nevro to Report Fourth Quarter and Full-Year 2021 Financial Results
REDWOOD CITY, Calif., Jan. 24, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...
Nevro's (NVRO) Senza Gets FDA Nod for Expanded Labeling for NSRBP
Nevro's (NVRO) receipt of the FDA's approval for expanded labeling of its Senza SCS System is expected to cater to underserved patients.
Nevro Announces FDA Approval for Expanded Labeling for its 10 kHz High Frequency Spinal Cord Stimulation System for T...
REDWOOD CITY, Calif., Jan. 19, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...
Clinical Data Presented at 2022 North American Neuromodulation Society (NANS) Annual Meeting Reinforce Significant an...
REDWOOD CITY, Calif., Jan. 18, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...
Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2021 Revenue
REDWOOD CITY, Calif., Jan. 10, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,...
Nevro's (NVRO) 10 kHz Therapy for Treatment of PDN Gets Coverage
Nevro (NVRO) receives coverage for its high-frequency 10 kHz therapy for the treatment of PDN.
Nevro (NVRO) Surges 5.2%: Is This an Indication of Further Gains?
Nevro (NVRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nevro Announces UnitedHealthcare Coverage for High-Frequency 10 kHz Therapy for the Treatment of Painful Diabetic Neu...
REDWOOD CITY, Calif., Jan. 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, ...
Nevro Announces Settlement of IP Litigation with Nalu Medical
REDWOOD CITY, Calif., Dec. 21, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today ...